<DOC>
	<DOCNO>NCT00423449</DOCNO>
	<brief_summary>This clinical trial determine safety tolerability MK0683 combination gemcitabine cisplatin and/or carboplatin .</brief_summary>
	<brief_title>Clinical Trial MK0683 Combination With FDA Approved Cancer Drugs Patients With Advanced NSCLC ( MK0683-058 )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Patient must histologicallyconfirmed metastatic locally advanced nonsmall cell lung cancer previously treat systemic chemotherapy receive nonplatinum nongemcitabine base neoadjuvant adjuvant chemotherapy last dose least 6 month prior study enrollment Patient chemotherapy , radiotherapy , biological therapy prior enter study , except adjuvant neoadjuvant chemotherapy , allow treatment tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Advanced Stage IIIB/IV Non-Small Cell Lung Cancer</keyword>
</DOC>